alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 522.2012 Prostalene. ( a ) *Specifications.* Each milliliter of solution contains 1 milligram of prostalene.
( b ) *Sponsor.* No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* Administer 5 micrograms per kilogram of body weight as a single subcutaneous injection.
( 2 ) *Indications for use.* For the control of estrus in mares.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[79 FR 16195, Mar. 25, 2014]
#### § 1301.01 Scope of this part 1301.

Procedures governing the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances pursuant to sections 301-304 and 1007-1008 of the Act (21 U.S.C. 821-824 and 957-958) are set forth generally by those sections and specifically by the sections of this part.

[62 FR 13945, Mar. 24, 1997]
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr.

, Chief Justice

Michael F. Cavanagh

Stephen J. Markman

Mary Beth Kelly

Brian K. Zahra

Bridget M. McCormack

David F. Viviano

, Justices

I, Larry S. Royster , Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

September 17, 2014

t0910 

# Order

Clerk September 17, 2014

149173

PEOPLE OF THE STATE OF MICHIG AN,

Plaintiff

- Appellee,

v SC: 149173

COA: 320286

Genesee CC: 13

- 033600

- FH

KELLY ANNETTE JACKSON,

Defendant

- Appellant.

_________________________________________/

On order of the Court, the application for leave to appeal the April 1, 2014 order

of the Court of Appeals is considered and, pursuant to MCR 7.302(H)(1), in lieu of

granting leave to appeal, we VACATE the sentence of the Genesee Circuit Court, and we

REMA ND this case to that court for resentencing. OV 2, MCL 777.32, must be scored at

0 points where the incendiary device was part of the process of manufacturing

methamphetamine and was not possessed or used as a weapon. People v Crabtree , 493

Mich 878 (201 2), citing People v Ball , 297 Mich App 121 (2012). In addition, the five

point score for OV 15, MCL 777.45, was proper on the ground that there was evidence of

delivery of the drugs. MCL 777.45(1)(h). A proper reading of MCL 777.45(1)(h)

reveals two alt ernative bases for scoring that OV at five points: (1) when the offense

involved the delivery or possession with intent to deliver marihuana or any other

controlled substance or counterfeit controlled substance; and (2) when the offense

involved possessio n of controlled substances or counterfeit controlled substances having

a value or under such circumstances as to indicate trafficking. In all other respects, leave

to appeal is DENIED, because we are not persuaded that the remaining question

presented should be reviewed by this Court.
§ 50.56 Wards. ( a ) Children who are wards of the State or any other agency, institution, or entity can be included in clinical investigations approved under § 50.53 or § 50.54 only if such clinical investigations are: ( 1 ) Related to their status as wards; or
( 2 ) Conducted in schools, camps, hospitals, institutions, or similar settings in which the majority of children involved as subjects are not wards.
( b ) If the clinical investigation is approved under paragraph (a) of this section, the IRB must require appointment of an advocate for each child who is a ward. ( 1 ) The advocate will serve in addition to any other individual acting on behalf of the child as guardian or in loco parentis.
( 2 ) One individual may serve as advocate for more than one child.
( 3 ) The advocate must be an individual who has the background and experience to act in, and agrees to act in, the best interest of the child for the duration of the child's participation in the clinical investigation.
( 4 ) The advocate must not be associated in any way (except in the role as advocate or member of the IRB) with the clinical investigation, the investigator(s), or the guardian organization.
§ 582.1975 Bleached beeswax. ( a ) *Product.* Bleached beeswax (white wax).
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
**Jaguar Cars Limited EMISSION DEFECT INFORMATION REPORT No. J08158D1A**

**Causal part name: SENSOR - MAF Causal part number: C2C7636** 

Issued: 15 April 2011 Page 1 of 2 Code of Federal Regulations. Title 40. Part 85. Subpart T. §85.1903 - Emissions Defect Information Report

(c)(1) The manufacturers corporate name.

Jaguar Cars Limited.

(c)(2) A description of the defect.

Owners report M.I.L. illumination or uneven running. Technicians find lean, rich, and MAF sensor codes stored (P0171, P0174, P0172, P0101, P0102, P010b) and replace mass air flow sensors.

Analysis reveals that 30% of MAF changes are followed by a related claim, suggesting that MAF replacement did not resolve the issue. An investigation is ongoing to determine root cause of MAF replacements.

(c)(3) A description of each class or category of vehicles potentially affected by the defect including make, model, model year, and such other information as may be required to identify these vehicles.

See table in section (c)(4)(i) below.

(c)(4) For each class or category of vehicle or engine described in response to paragraph (c)(3) of this section, the following shall also be provided:

(c)(4)(i) The number of vehicles or engines known or estimated to have the defect and an explanation of the means by which this number was determined.

MODEL

YEAR TEST GROUP MODEL SALES DEFECTS

2005 5JCXV04.2DSB XJR; SUPER V8; S-TYPE R 2348 54

2006 6JCXV04.2DSK XJR; SUPER V8; S-TYPE R 1112 33

2007 7JCXV04.2DNK XK; XJ8; XJ8L; VDP LWB; S-TYPE 4.2 9182 50

2007 7JCXV04.2DSK XKR; XJR; SUPER V8; S-TYPE R 2290 50

The above data was taken from Jaguar's warranty tracking report dated 2010 Q4.

Issues resolved first time by changing the MAF sensor are listed as defects.

(c)(4)(ii) The address of the plant at which the potentially defective vehicles or engines were produced.

Jaguar Castle Bromwich Plant, Birmingham, England. 

### EPA EDIR# 4211 Received: April 18, 2010**Jaguar Cars Limited EMISSION DEFECT INFORMATION REPORT No. J08158D1A**

**Causal part name: SENSOR - MAF Causal part number: C2C7636** 

Issued: 15 April 2011 Page 2 of 2 (c)(5) An evaluation of the emissions impact of the defect and a description of any driveability problems which a defective vehicle might exhibit.

No adverse impact on emissions has been associated with the MAF sensor in this investigation.

No adverse impact on driveability has been associated with the MAF sensor in this investigation.

M.I.L. illumination associated with the MAF sensor has been noted in this investigation.

(c)(6) Available emissions data which relate to the defect.

Not applicable.

(c)(7) An indication of any anticipated manufacturer follow-up.

Investigation into root cause of defect will continue and will be reported upon completion. 

### EPA EDIR# 4211 Received: April 18, 2010
Editorial Note on Part 175
Editorial Note: Nomenclature changes to part 175 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; and 70 FR 72074, Dec. 1, 2005.

§ 175.350 Vinyl acetate/crotonic acid copolymer. A copolymer of vinyl acetate and crotonic acid may be safely used as a coating or as a component of a coating which is the food-contact surface of polyolefin films intended for packaging food, subject to the provisions of this section. ( a ) The copolymer may contain added optional substances to impart desired properties.
( b ) The quantity of any optional substance does not exceed the amount reasonably required to accomplish the intended physical or technical effect nor any limitations further provided.
( c ) Any optional substance that is the subject of a regulation in parts 174, 175, 176, 177, 178, and § 179.45 of this chapter conforms with any specifications in such regulation.
( d ) Optional substances as provided in paragraph (a) of this section include: ( 1 ) Substances generally recognized as safe in food.
( 2 ) Substances subject to prior sanction or approval for uses with a copolymer of vinyl acetate and crotonic acid and used in accordance with such sanction or approval.
( 3 ) Substances identified in this subparagraph and subject to such limitations as are provided: List of substances
Limitations Silica Japan wax
( e ) Copolymer of vinyl acetate and crotonic acid used as a coating or as a component of a coating conforming with the specifications of paragraph (e)(1) of this section are used as provided in paragraph (e)(2) of this section. ( 1 ) *Specifications.* ( i ) The chloroform-soluble portion of the water extractives of the coated film obtained with distilled water at 120 °F for 24 hours does not exceed 0.5 milligram per square inch of coated surface.
( ii ) The chloroform-soluble portion of the *n-*heptane extractives of the coated film obtained with *n-*heptane at 70 °F for 30 minutes does not exceed 0.5 milligram per square inch of coated surface.
( 2 ) *Conditions of use.* The copolymer of vinyl acetate and crotonic acid is used as a coating or as a component of a coating for polyolefin films for packaging bakery products and confectionery.
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               JUN-30-1998
<CASH>                                       3,226,434
<SECURITIES>                                         0
<RECEIVABLES>                                2,203,598
<ALLOWANCES>                                    10,000
<INVENTORY>                                  2,418,413
<CURRENT-ASSETS>                             8,589,249
<PP&E>                                      89,212,455
<DEPRECIATION>                               7,629,441
<TOTAL-ASSETS>                              92,206,202<F1>
<CURRENT-LIABILITIES>                        6,939,842
<BONDS>                                      9,580,761
<PREFERRED-MANDATORY>                       15,988,455
<PREFERRED>                                          0
<COMMON>                                        38,438
<OTHER-SE>                                  57,321,346
<TOTAL-LIABILITY-AND-EQUITY>                92,206,202
<SALES>                                     16,680,253<F2>
<TOTAL-REVENUES>                            16,680,253<F2>
<CGS>                                       12,364,940
<TOTAL-COSTS>                               22,371,218<F3>
<OTHER-EXPENSES>                              (41,877)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             362,010
<INCOME-PRETAX>                            (6,011,098)
<INCOME-TAX>                               (2,011,655)
<INCOME-CONTINUING>                        (3,999,443)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (3,999,443)
<EPS-PRIMARY>                                   (0.52)
<EPS-DILUTED>                                   (0.52)
<FN>
<F1>Total Assets includes Assets Held for Sale of $1,184,000.
<F2>Sales and Total Revenues are net of federal and state excise taxes.
<F3>Total Costs includes Special Valuation Provision of $5,172,650.
</FN>
        

</TABLE>
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from Swift Energy
Pension Partners 1992-B, Ltd.'s balance sheet and statement of operations con-
tained in its Form 10-Q for the quarter ended June 30, 1997 and is qualified in
its entirety by reference to such financial statements.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                              DEC-31-1997
<PERIOD-END>                                   JUN-30-1997
<CASH>                                         55,926
<SECURITIES>                                   0
<RECEIVABLES>                                  180,514
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                               242,758
<PP&E>                                         5,598,811
<DEPRECIATION>                                 (4,187,128)
<TOTAL-ASSETS>                                 1,654,441
<CURRENT-LIABILITIES>                          7,615
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       0
<OTHER-SE>                                     1,646,826
<TOTAL-LIABILITY-AND-EQUITY>                   1,654,441
<SALES>                                        333,613
<TOTAL-REVENUES>                               336,093
<CGS>                                          0
<TOTAL-COSTS>                                  156,375<F1>
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             0
<INCOME-PRETAX>                                126,347
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            126,347
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   126,347
<EPS-PRIMARY>                                  0
<EPS-DILUTED>                                  0
<FN>
<F1>Includes lease operating expenses, production taxes and depreciation,
depletion and amortization expense.  Excludes general and administrative and
interest expense.
</FN>
        


</TABLE>
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7423 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7423

 To designate the facility of the United States Postal Service located 
 at 103 Benedette Street in Rayville, Louisiana, as the ``Luke Letlow 
                        Post Office Building''.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 20, 2024

  Mr. Scalise (for himself, Ms. Letlow, Mr. Johnson of Louisiana, Mr. 
   Higgins of Louisiana, Mr. Carter of Louisiana, and Mr. Graves of 
  Louisiana) introduced the following bill; which was referred to the 
               Committee on Oversight and Accountability

_______________________________________________________________________

                                 A BILL

 
 To designate the facility of the United States Postal Service located 
 at 103 Benedette Street in Rayville, Louisiana, as the ``Luke Letlow 
                        Post Office Building''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. LUKE LETLOW POST OFFICE BUILDING.

    (a) Designation.--The facility of the United States Postal Service 
located at 103 Benedette Street in Rayville, Louisiana, shall be known 
and designated as the ``Luke Letlow Post Office Building''.
    (b) References.--Any reference in a law, map, regulation, document, 
paper, or other record of the United States to the facility referred to 
in subsection (a) shall be deemed to be a reference to the ``Luke 
Letlow Post Office Building''.
                                 <all>
```
#### Connecticut Bank and Trust Company, Executor (Estate of Marie P. Jensen), et al. *v.*Ludis Upenieks et al.

The motion by the defendants Ludis Upenieks and Antoinette Pesce to dismiss the appeal from the Superior Court in Tolland County is granted.

*639
      *Herman Yules,*for the appellee (named defendant).

*Jules A. Karp,*for the appellee (defendant Antoinette Pesce).

Argued June 3

decided June 3, 1969
[Nos. 39404-5-I; 39434-7-I.

Division One.

December 1, 1997.]

#### The State of Washington, *Respondent,*v. Darryl Saulsbury, *Appellant. In the Matter of the Personal Restraint of*Darryl Saulsbury, *Petitioner.*

Appeal from a judgment of the Superior Court for King County, No. 96-1-01362-1, Janice Niemi, J., entered August 26, 1996, together with a petition for relief from personal restraint. Judgment *affirmed*and petition *dismissed*by unpublished per curiam opinion.
# C_2015389EN.01001201.xml

| 23.11.2015 | EN | Official Journal of the European Union | C 389/12 |
| --- | --- | --- | --- |

23.11.2015

EN

Official Journal of the European Union

C 389/12

---

Appeal brought on 24 November 2014 by Giorgio Giorgis against the judgment of the General Court (Seventh Chamber) delivered on 25 September 2014 in Case T-474/12: Giorgio Giorgis v Office for Harmonisation in the Internal Market (Trade Marks and Designs)

(Case C-531/14 P)

(2015/C 389/14)

Language of the case: English

Parties

Parties

Appellant: Giorgio Giorgis (represented by: I.M. Prado, A. Tornato, avvocati)

Appellant:

Other parties to the proceedings: Office for Harmonisation in the Internal Market (Trade Marks and Designs), Comigel SAS

Other parties to the proceedings:

By order of 2 September 2015 the Court of Justice (Sixth Chamber) has dismissed the appeal and ordered Mr Giorgio Giorgis to bear his own costs.

---
Court of Appeals of the State of Georgia Clerk's Office, Atlanta, May 03, 2018. I certify that the above is a true extract from the minutes of the Court of Appeals of Georgia. Witness my signature and the seal of said court hereto affixed the day and year last above written. , Clerk. 

# Court of Appeals of the State of Georgia
ATLANTA, May 03, 2018 The Court of Appeals hereby passes the following order A18D0412. KIMEX BOAT ROCK 1183, LLC v. PRINCIPAL LIEN SERVICES, LLC.
Upon consideration of the Application for Discretionary Appeal, it is ordered that it be hereby DENIED.
LC NUMBERS: 17GC000464
§ 520.2123b Spectinomycin powder. ( a ) *Specifications.* Each gram (g) of powder contains spectinomycin dihydrochloride pentahydrate equivalent to 0.5 g spectinomycin.
( b ) *Sponsor.* See No. 061133 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See § 556.600 of this chapter.
( d ) *Conditions of use in chickens.* It is administered in the drinking water of growing chickens as follows: ( 1 ) *Indications for use and amounts.* ( i ) As an aid in controlling infectious synovitis due to *Mycoplasma synoviae* in broiler chickens, administer 1 g per gallon of water as the only source of drinking water for the first 3 to 5 days of life.
( ii ) As an aid in the prevention or control of losses due to CRD associated with *M. gallisepticum* (PPLO) in growing chickens, administer 2 g per gallon of water as the only source of drinking water for the first 3 days of life and for 1 day following each vaccination.
( 2 ) *Limitations.* Do not administer to laying chickens. Do not administer within 5 days of slaughter. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[73 FR 6607, Feb. 5, 2008, as amended at 81 FR 94990, Dec. 27, 2016; 84 FR 8973, Mar. 13, 2019]
§ 524.775 Emodepside and praziquantel. ( a ) *Specifications.* Each milliliter of solution contains 21.4 milligrams (mg) emodepside and 85.7 mg praziquantel.
( b ) *Sponsor.* See No. 058198 in § 510.600(c) of this chapter.
( c ) *Conditions of use in cats* — ( 1 ) *Amount.* The recommended minimum dose is 1.36 mg/pound (lb) (3 mg/kilogram (kg)) emodepside and 5.45 mg/lb (12 mg/kg) praziquantel applied as a single topical dose.
( 2 ) *Indications for use.* For the treatment and control of hookworm infections caused by *Ancylostoma tubaeforme* (adults, immature adults, and fourth stage larvae), roundworm infections caused by *Toxocara cati* (adults and fourth stage larvae), and tapeworm infections caused by *Dipylidium caninum* (adults) and *Taenia taeniaeformis* (adults).
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[72 FR 42291, Aug. 2, 2007, as amended at 86 FR 14820, Mar. 19, 2021]
§ 573.550 25-hydroxyvitamin D3. The food additive, 25-hydroxyvitamin D3, may be safely used in accordance with the following prescribed conditions: ( a ) The additive is used or intended for use as a source of vitamin D3 activity in animal feed or drinking water in accordance with good manufacturing and feeding practices as follows: ( 1 ) In feed or drinking water of layer and breeder chickens not to exceed 69 parts per billion (ppb) in feed or 34.5 ppb in drinking water.
( 2 ) In feed or drinking water of turkeys not to exceed: ( i ) 92 ppb in feed; or
( ii ) In drinking water, 25 ppb for turkeys up to 3 weeks of age, 36 ppb for turkeys from 4 to 11 weeks of age, or 45 ppb for turkeys over 11 weeks of age.
( b ) The additive consists of not less than 94 percent 25-hydroxyvitamin D3 (9,10-secocholesta-5,7,10(19)-triene-3β, 25-diol).
( c ) The additive meets the following specifications: ( 1 ) Not more than 1 percent of any individual sterol.
( 2 ) Not more than 5 percent water.
( 3 ) Not more than 20 parts per million (ppm) lead.
( 4 ) Not more than 20 ppm aluminum.
( 5 ) Not more than 1.0 percent solvents and non-detectable levels of 2′, 4′, 5′, 7′ tetraiodofluorescin.
( 6 ) Not more than 1 ppb 1, 25-dihydroxycholecalciferol.
( d ) To assure safe use of the additive, in addition to the other information required by the Federal Food, Drug, and Cosmetic Act, the label and labeling shall contain: ( 1 ) The name of the additive.
( 2 ) A statement to indicate the maximum use level of 25-hydroxyvitamin D3 must not exceed 69 ppb in feed or 34.5 ppb in drinking water for layer and breeder chickens.
( 3 ) A statement to indicate for turkeys the maximum use level of 25-hydroxyvitamin D3 must not exceed 92 ppb in feed; or in drinking water, 25 ppb for turkeys up to 3 weeks of age, 36 ppb for turkeys from 4 to 11 weeks of age, or 45 ppb for turkeys over 11 weeks of age.
( 4 ) Adequate use directions to ensure that 25-hydroxyvitamin D3 (and all premixes) is uniformly blended throughout the feed or drinking water.
( 5 ) An expiration date on all premix labeling.
( 6 ) A statement on all premix labeling (feed and drinking water forms) that 25-hydroxyvitamin D3 cannot be used simultaneously in both feed and water.
[83 FR 49486, Oct. 2, 2018]
§ 640.90 Plasma Protein Fraction (Human). ( a ) *Proper name and definition.* The proper name of the product shall be Plasma Protein Fraction (Human). The product is defined as a sterile solution of protein composed of albumin and globulin, derived from human plasma.
( b ) *Source material.* The source material of Plasma Protein Fraction (Human) shall be plasma recovered from Whole Blood prepared as prescribed in §§ 640.1 through 640.5, or Source Plasma prepared as prescribed in §§ 640.60 through 640.76.
( c ) *Additives in source material.* Source material shall not contain an additive unless it is shown that the processing method yields a final product free of the additive to such extent that the continued safety, purity, potency, and effectiveness of the final product will not be adversely affected.
[42 FR 27583, May 31, 1977, as amended at 64 FR 26286, May 14, 1999]